| P50 | author | David C. Montefiori | Q63302725 |
| | Andrea Carfì | Q88702827 |
| | Susan W Barnett | Q89214866 |
| | Antu K Dey | Q89308546 |
| | Indresh K Srivastava | Q122828624 |
| | Karin Hartog | Q122828630 |
| P2093 | author name string | Brian Burke | |
| | Loïc Martin | |
| | Pascal Kessler | |
| | Michael Franti | |
| | Ying Lian | |
| | Anthony R Geonnotti | |
| | Grégoire Martin | |
| | Yide Sun | |
| | Avishek Nandi | |
| | Klara Sirokman | |
| P2860 | cites work | Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 |
| | Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design | Q24679395 |
| | Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site | Q27316899 |
| | Combinatorial Optimization of a CD4-Mimetic Miniprotein and Cocrystal Structures with HIV-1 gp120 Envelope Glycoprotein | Q27651139 |
| | Molecular architecture of native HIV-1 gp120 trimers | Q27651385 |
| | Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 | Q27658449 |
| | Antibody neutralization and escape by HIV-1 | Q29547345 |
| | Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 |
| | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 |
| | Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 |
| | Structure of a V3-containing HIV-1 gp120 core | Q29619014 |
| | Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 |
| | HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 |
| | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 |
| | Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 |
| | Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 |
| | B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. | Q33373664 |
| | Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection | Q33410222 |
| | Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. | Q33645053 |
| | Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design | Q33717477 |
| | Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. | Q33759392 |
| | Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant | Q33877513 |
| | Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins | Q39668082 |
| | Measuring HIV neutralization in a luciferase reporter gene assay | Q39914262 |
| | Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. | Q40210715 |
| | Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope | Q40281145 |
| | The rational design of an AIDS vaccine | Q40348550 |
| | Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | Q40682865 |
| | DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques | Q40904272 |
| | A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry | Q43506030 |
| | Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. | Q44455932 |
| | Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization | Q44592013 |
| | Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes | Q45052086 |
| | Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope | Q46331384 |
| | Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection | Q67967877 |
| | Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120?CD4 complex in transgenic mice that produce human immunoglobulins | Q79078538 |
| | Comparing antigenicity and immunogenicity of engineered gp120. | Q33984309 |
| | An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction | Q34092668 |
| | Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques | Q34154514 |
| | A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 |
| | Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus | Q34332284 |
| | A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response | Q34357078 |
| | Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region | Q34471760 |
| | A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers | Q34743297 |
| | Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals | Q34962766 |
| | Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo | Q35024202 |
| | Stabilization of HIV-1 Envelope in the CD4-bound Conformation through Specific Cross-linking of a CD4 Mimetic | Q35065249 |
| | Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 |
| | Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens | Q36141515 |
| | Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 |
| | N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus | Q36565090 |
| | Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding | Q36649958 |
| | Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates | Q36656036 |
| | Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding | Q36795606 |
| | Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity | Q36797873 |
| | Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody | Q36821885 |
| | Roles of HIV-1 Env variable regions in viral neutralization and vaccine development | Q37017791 |
| | Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 |
| | Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. | Q37072702 |
| | A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide | Q37102810 |
| | Toward an AIDS vaccine | Q37158259 |
| | Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge | Q37297052 |
| | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors | Q37333772 |
| | Immunogenicity of HIV-1 envelope glycoprotein oligomers | Q37667740 |
| | Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits | Q38356290 |
| | Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. | Q38924919 |
| | Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate | Q39484956 |
| | CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides | Q39550847 |
| | The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region | Q39602963 |
| | Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein | Q39608920 |
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | e30233 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein | |
| P478 | volume | 7 | |